Innoviva (INVA) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Innoviva (INVA) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 45.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 91.31% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Innoviva | 1.58 Bn | 979.49 Mn | 75.83 Mn | 74.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.92% |
| Dec 31, 2025 | -2.43% |
| Sep 30, 2025 | -27.62% |
| Jun 30, 2025 | 307.82% |
| Mar 31, 2025 | -70.47% |
| Dec 31, 2024 | 29.78% |
| Sep 30, 2024 | -77.04% |
| Jun 30, 2024 | -33.70% |
| Mar 31, 2024 | -27.06% |
| Dec 31, 2023 | -73.93% |
| Sep 30, 2023 | 61.20% |
| Jun 30, 2023 | -74.46% |
| Mar 31, 2023 | -18.93% |
| Dec 31, 2022 | -32.88% |
| Sep 30, 2022 | 92.11% |
| Jun 30, 2022 | -70.81% |
| Mar 31, 2022 | -22.43% |
| Dec 31, 2021 | -29.47% |
| Sep 30, 2021 | 75.72% |
| Jun 30, 2021 | 17.65% |